|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 8/22/22 Can B Corp. 10-Q 6/30/22 62:5.5M M2 Compliance LLC/FA |
Document/Exhibit Description Pages Size
1: 10-Q Quarterly Report HTML 1.67M
2: EX-31.1 Certification -- §302 - SOA'02 HTML 22K
3: EX-31.2 Certification -- §302 - SOA'02 HTML 22K
4: EX-32.1 Certification -- §906 - SOA'02 HTML 19K
5: EX-32.2 Certification -- §906 - SOA'02 HTML 19K
11: R1 Cover HTML 66K
12: R2 Consolidated Balance Sheets HTML 144K
13: R3 Consolidated Balance Sheets (Parenthetical) HTML 51K
14: R4 Consolidated Statement of Operations HTML 88K
15: R5 Consolidated Statement of Stockholders' Equity HTML 102K
16: R6 Consolidated Statement of Cash Flows HTML 120K
17: R7 Organization and Description of Business HTML 24K
18: R8 Liquidity HTML 22K
19: R9 Basis of Presentation and Summary of Significant HTML 35K
Accounting Policies
20: R10 Fair Value Measurements HTML 67K
21: R11 Asset Acquisitions HTML 40K
22: R12 Inventories HTML 29K
23: R13 Property and Equipment HTML 39K
24: R14 Intangible Assets HTML 42K
25: R15 Notes and Loans Payable HTML 98K
26: R16 Stockholders? Equity HTML 42K
27: R17 Stock Options HTML 56K
28: R18 Income Taxes HTML 22K
29: R19 Related Party Transactions HTML 24K
30: R20 Commitments and Contingencies HTML 28K
31: R21 Subsequent Events HTML 24K
32: R22 Basis of Presentation and Summary of Significant HTML 50K
Accounting Policies (Policies)
33: R23 Fair Value Measurements (Tables) HTML 70K
34: R24 Inventories (Tables) HTML 29K
35: R25 Property and Equipment (Tables) HTML 36K
36: R26 Intangible Assets (Tables) HTML 41K
37: R27 Stock Options (Tables) HTML 57K
38: R28 Commitments and Contingencies (Tables) HTML 25K
39: R29 Liquidity (Details Narrative) HTML 34K
40: R30 Schedule of Carrying Value and Fair value HTML 26K
(Details)
41: R31 Schedule of Fair Value of the Warrants Outstanding HTML 30K
(Details)
42: R32 Schedule of Change in Fair Value of the Warrant HTML 23K
Liabilities (Details)
43: R33 Asset Acquisitions (Details Narrative) HTML 67K
44: R34 Schedule of Inventories (Details) HTML 23K
45: R35 Summary of Property, Plant and Equipment (Details) HTML 34K
46: R36 Property and Equipment (Details Narrative) HTML 19K
47: R37 Schedule of Intangible Assets (Details) HTML 25K
48: R38 Schedule of Estimated Amortization Expenses HTML 33K
(Details)
49: R39 Intangible Assets (Details Narrative) HTML 19K
50: R40 Notes and Loans Payable (Details Narrative) HTML 223K
51: R41 Stockholders? Equity (Details Narrative) HTML 81K
52: R42 Summary of Stock Options Activity (Details) HTML 49K
53: R43 Schedule of Non-Vested Option Shares (Details) HTML 34K
54: R44 Related Party Transactions (Details Narrative) HTML 29K
55: R45 Schedule of Future Minimum Lease Payments Under HTML 25K
Non-cancellable Operating Leases (Details)
56: R46 Commitments and Contingencies (Details Narrative) HTML 19K
57: R47 Subsequent Events (Details Narrative) HTML 24K
60: XML IDEA XML File -- Filing Summary XML 104K
58: XML XBRL Instance -- form10-q_htm XML 1.18M
59: EXCEL IDEA Workbook of Financial Reports XLSX 103K
7: EX-101.CAL XBRL Calculations -- canb-20220630_cal XML 154K
8: EX-101.DEF XBRL Definitions -- canb-20220630_def XML 373K
9: EX-101.LAB XBRL Labels -- canb-20220630_lab XML 824K
10: EX-101.PRE XBRL Presentations -- canb-20220630_pre XML 596K
6: EX-101.SCH XBRL Schema -- canb-20220630 XSD 120K
61: JSON XBRL Instance as JSON Data -- MetaLinks 300± 415K
62: ZIP XBRL Zipped Folder -- 0001493152-22-023686-xbrl Zip 195K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
(Mark One)
i ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended i June 30, i 2022 /
i ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from __________ to __________
COMMISSION FILE NUMBER: i 333-208293
(Exact name of registrant as specified in its charter)
| i Florida | i 20-3624118 | |
(State or other jurisdiction of incorporation or organization) |
(I.R.S. Employer Identification No.) |
i 960 South Broadway, i Suite 120
i Hicksville, i NY i 11801
(Address of principal executive offices)
(Registrant’s telephone number, including area code)
Canbiola, Inc.
(Former name, former address and former fiscal, if changed since last report)
Securities Registered Pursuant to Section 12(b) of the Act:
| Tile of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
| None | CANB | N/A |
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. i Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). i Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
| Large accelerated filer | ☐ | Accelerated filer | ☐ |
| i Non-accelerated filer | ☒ | Smaller reporting company | i ☒ |
| Emerging Growth Company | i ☐ | ||
| (Do not check if smaller reporting company) |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). ☐ Yes ☒ i No
The number of shares of the registrant’s only class of common stock issued and outstanding as of August 21, 2022 is .
C:
Can B Corp.
FORM 10-Q
TABLE OF CONTENTS
C:
| C: 2 |
PART 1 – FINANCIAL INFORMATION
Can B̅ Corp. and Subsidiaries
Consolidated Balance Sheets
| (Unaudited) | ||||||||
| June 30, | December 31, | |||||||
| 2022 | 2021 | |||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | i 124,058 | $ | i 449,001 | ||||
| Accounts receivable, less allowance for doubtful accounts of $ i i 547,241 / | i 4,954,293 | i 3,646,677 | ||||||
| Inventory | i 3,162,074 | i 2,553,438 | ||||||
| Note receivable | - | i 2,898 | ||||||
| Prepaid expenses | i 4,451 | i 1,625 | ||||||
| Total current assets | i 8,244,876 | i 6,653,639 | ||||||
| Property and equipment, net | i 6,434,380 | i 7,052,926 | ||||||
| Other assets: | ||||||||
| Deposits | i 165,787 | i 165,787 | ||||||
| Intangible assets, net | i 365,606 | i 369,015 | ||||||
| Operating lease right-of-use-asset, net | i 1,810,796 | i 2,220,134 | ||||||
| Other noncurrent assets | i 13,139 | i 13,139 | ||||||
| Total other assets | i 2,355,328 | i 2,768,075 | ||||||
| Total assets | $ | i 17,034,584 | $ | i 16,474,640 | ||||
| Liabilities and Stockholders’ Equity | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | i 2,730,495 | $ | i 1,163,284 | ||||
| Accrued expenses | i 157,681 | i 2,407,528 | ||||||
| Due to related party | i 245,434 | i 218,273 | ||||||
| Notes and loans payable, net | i 6,314,585 | i 4,865,749 | ||||||
| Warrant liabilities | i 172,269 | - | ||||||
| Operating lease liability - current | i 830,285 | i 808,223 | ||||||
| Total current liabilities | i 10,450,749 | i 9,463,057 | ||||||
| Long-term liabilities: | ||||||||
| Operating lease liability - noncurrent | i 944,182 | i 1,392,068 | ||||||
| Total long-term liabilities | i 944,182 | i 1,392,068 | ||||||
| Total liabilities | $ | i 11,394,931 | $ | i 10,855,125 | ||||
| Commitments and contingencies (Note 14) | - | |||||||
| Stockholders’ equity: | ||||||||
| Preferred stock, authorized shares: | ||||||||
| Series A Preferred stock, i i no / par value: shares authorized, shares and shares issued and outstanding at June 30, 2022 and December 31, 2021, respectively | i 5,320,000 | i 28,440,000 | ||||||
| Series B Preferred stock, $ par value: shares authorized, issued and outstanding | - | - | ||||||
| Series C Preferred stock, $ par value: shares authorized, issued and outstanding | i 207,000 | i 207,000 | ||||||
| Series D Preferred stock, $ par value: shares authorized, issued and outstanding | i 2 | i 2 | ||||||
| Preferred Stock Value | ||||||||
| Common stock, i i no / par value; shares authorized, and issued and outstanding at June 30, 2022 and December 31, 2021, respectively | i 77,256,363 | i 49,676,847 | ||||||
| Common stock issuable, i i no / par value; and shares at June 30, 2022 and December 31, 2021, respectively | i 119,586 | - | ||||||
| Treasury stock | ( i 572,678 | ) | ( i 572,678 | ) | ||||
| Additional paid-in capital | i 6,206,822 | i 5,635,003 | ||||||
| Accumulated deficit | ( i 82,897,442 | ) | ( i 77,766,659 | ) | ||||
| Total stockholders’ equity | i 5,639,653 | i 5,619,515 | ||||||
| Total liabilities and stockholders’ equity | $ | i 17,034,584 | $ | i 16,474,640 | ||||
See notes to consolidated financial statements
C:
| 3 |
Can B̅ Corp. and Subsidiaries
Consolidated Statement of Operations
See notes to consolidated financial statements
C:
| 4 |
Can B̅ Corp. and Subsidiaries
Consolidated Statement of Stockholders’ Equity
| Three Months Ended June 30, 2022 and 2021 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Series A | Series B | Series C | Series D | Common | Additional | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Preferred Stock | Preferred Stock | Preferred Stock | Preferred Stock | Common Stock | Stock | Treasury Stock | Paid-in | Accumulated | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Shares | Amount | Shares | Amount | Shares | Amount | Shares | Amount | Shares | Amount | Issuable | Shares | Amount | Capital | Deficit | Total | |||||||||||||||||||||||||||||||||||||||||||||||||
| Three months ended June 30, 2022 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Balance, April 1, 2022 | i 5 | $ | i 5,320,000 | - | $ | - | i 23 | $ | i 207,000 | i 1,950 | $ | i 2 | i 3,264,566 | $ | i 76,219,018 | $ | i 119,586 | i 36,248 | $ | ( i 572,678 | ) | $ | i 6,206,822 | $ | ( i 81,251,556 | ) | $ | i 6,248,194 | ||||||||||||||||||||||||||||||||||||
| Issuance of common stock for services rendered | - | - | - | - | - | - | - | - | i 181,183 | i 1,037,345 | - | - | - | - | i 1,037,345 | |||||||||||||||||||||||||||||||||||||||||||||||||
| Net loss | - | - | - | - | - | - | - | - | - | - | - | - | - | - | ( i 1,645,886 | ) | ( i 1,645,886 | ) | ||||||||||||||||||||||||||||||||||||||||||||||
| Balance, June 30, 2022 | i 5 | $ | i 5,320,000 | i 0 | $ | - | i 23 | $ | i 207,000 | i 1,950 | $ | i 2 | i 3,445,749 | $ | i 77,256,363 | $ | i 119,586 | i 36,248 | $ | ( i 572,678 | ) | $ | i 6,206,822 | $ | ( i 82,897,442 | ) | $ | i 5,639,653 | ||||||||||||||||||||||||||||||||||||
| Three months ended June 30, 2021 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Balance, April 1, 2021 | i 20 | $ | i 28,440,000 | - | $ | - | i 473 | $ | i 4,257,000 | i 1,950 | $ | i 2 | i 1,111,177 | $ | i 35,831,826 | $ | - | i 36,248 | $ | ( i 572,678 | ) | $ | i 2,724,689 | $ | ( i 67,777,146 | ) | $ | i 2,903,693 | ||||||||||||||||||||||||||||||||||||
| Issuance of common stock for services rendered | - | - | - | - | - | - | - | - | i 18,357 | i 350,913 | - | - | - | - | - | i 350,913 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Issuance of common stock warrants and commitment shares in connection with convertible promissory note | - | - | - | - | - | - | - | - | - | - | - | - | - | i 662,062 | - | i 662,062 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Net loss | - | - | - | - | - | - | - | - | - | - | - | - | - | - | ( i 2,739,989 | ) | ( i 2,739,989 | ) | ||||||||||||||||||||||||||||||||||||||||||||||
| Balance, June 30, 2021 | i 20 | $ | i 28,440,000 | - | $ | - | i 473 | $ | i 4,257,000 | i 1,950 | $ | i 2 | i 1,129,534 | $ | i 36,182,739 | $ | - | i 36,248 | $ | ( i 572,678 | ) | $ | i 3,386,751 | $ | ( i 70,517,135 | ) | $ | i 1,176,679 | ||||||||||||||||||||||||||||||||||||
Six Months Ended June 30, 2022 and 2021
| Series A | Series B | Series C | Series D | Common | Additional | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Preferred Stock | Preferred Stock | Preferred Stock | Preferred Stock | Common Stock | Stock | Treasury Stock | Paid-in | Accumulated | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Shares | Amount | Shares | Amount | Shares | Amount | Shares | Amount | Shares | Amount | Issuable | Shares | Amount | Capital | Deficit | Total | |||||||||||||||||||||||||||||||||||||||||||||||||
| Six months ended June 30, 2022 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Balance, January 1, 2022 | i 20 | $ | i 28,440,000 | - | $ | - | i 23 | $ | i 207,000 | i 1,950 | $ | i 2 | i 2,834,755 | $ | i 49,676,847 | $ | - | i 36,248 | $ | ( i 572,678 | ) | $ | i 5,635,003 | $ | ( i 77,766,659 | ) | $ | i 5,619,515 | ||||||||||||||||||||||||||||||||||||
| Conversion of Series A Preferred stock to Common stock | ( i 15 | ) | ( i 23,120,000 | ) | - | - | - | - | - | - | i 33,345 | i 23,120,000 | - | - | - | - | - | - | ||||||||||||||||||||||||||||||||||||||||||||||
| Sale of common stock | - | - | - | - | - | - | - | - | i 51,282 | i 500,000 | - | - | - | - | - | i 500,000 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Issuance of common stock in lieu of note interest repayments | - | - | - | - | - | - | - | - | i 10,150 | i 73,078 | - | - | - | - | - | i 73,078 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Issuance of common stock for services rendered | - | - | - | - | - | - | - | - | i 312,008 | i 2,020,274 | i 119,586 | - | - | - | - | i 2,139,860 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Issuance of common stock for equipment | - | - | - | - | - | - | - | - | i 13,704 | i 98,666 | - | - | - | - | - | i 98,666 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Issuance of common stock for asset acquisition | - | - | - | - | - | - | - | - | i 190,505 | i 1,767,498 | - | - | - | - | - | i 1,767,498 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Stock-based compensation | - | - | - | - | - | - | - | - | - | - | - | - | - | i 571,819 | - | i 571,819 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Net loss | - | - | - | - | - | - | - | - | - | - | - | - | - | - | ( i 5,130,783 | ) | ( i 5,130,783 | ) | ||||||||||||||||||||||||||||||||||||||||||||||
| Balance, June 30, 2022 | i 5 | $ | i 5,320,000 | i 0 | $ | - | i 23 | $ | i 207,000 | i 1,950 | $ | i 2 | i 3,445,749 | $ | i 77,256,363 | $ | i 119,586 | i 36,248 | $ | ( i 572,678 | ) | $ | i 6,206,822 | $ | ( i 82,897,442 | ) | $ | i 5,639,653 | ||||||||||||||||||||||||||||||||||||
| Six months ended June 30, 2021 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Balance, January 1, 2021 | i 20 | $ | i 28,440,000 | - | $ | - | i 623 | $ | i 5,607,000 | - | $ | - | i 369,639 | $ | i 30,874,270 | $ | - | i 36,248 | $ | ( i 572,678 | ) | $ | i 2,724,689 | $ | ( i 65,597,264 | ) | $ | i 1,476,017 | ||||||||||||||||||||||||||||||||||||
| Issuance of preferred stock | - | - | - | - | - | - | i 1,950 | i 2 | - | - | - | - | - | - | - | i 2 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Conversion of Series C Preferred stock to common stock | - | - | - | - | ( i 150 | ) | ( i 1,350,000 | ) | - | - | i 250,000 | i 1,350,000 | - | - | - | - | - | - | ||||||||||||||||||||||||||||||||||||||||||||||
| Sale of common stock | - | - | - | - | - | - | - | - | i 382,133 | i 2,866,000 | - | - | - | - | - | i 2,866,000 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Issuance of common stock in lieu of note repayments | - | - | - | - | - | - | - | - | i 77,017 | i 537,748 | - | - | - | - | - | i 537,748 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Issuance of common stock for services rendered | - | - | - | - | - | - | - | - | i 27,074 | i 417,048 | - | - | - | - | - | i 417,048 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Issuance of common stock for asset acquisition | - | - | - | - | - | - | - | - | i 23,670 | i 137,673 | - | - | - | - | - | i 137,673 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Issuance of common stock warrants and commitment shares in connection with convertible promissory note | - | - | - | - | - | - | - | - | - | - | - | - | - | i 662,062 | - | i 662,062 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Net loss | - | - | - | - | - | - | - | - | - | - | - | - | - | - | ( i 4,919,871 | ) | ( i 4,919,871 | ) | ||||||||||||||||||||||||||||||||||||||||||||||
| Balance, June 30, 2021 | i 20 | $ | i 28,440,000 | - | $ | - | i 473 | $ | i 4,257,000 | i 1,950 | $ | i 2 | i 1,129,534 | $ | i 36,182,739 | $ | - | i 36,248 | $ | ( i 572,678 | ) | $ | i 3,386,751 | $ | ( i 70,517,135 | ) | $ | i 1,176,679 | ||||||||||||||||||||||||||||||||||||
See notes to consolidated financial statements
C:C:
| 5 |
Can B̅ Corp. and Subsidiaries
Consolidated Statement of Cash Flows
| Six Months Ended | ||||||||
| June 30, | ||||||||
| 2022 | 2021 | |||||||
| Operating activities: | ||||||||
| Net loss | $ | ( i 5,130,783 | ) | $ | ( i 4,919,871 | ) | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||
| Stock-based compensation | i 571,819 | - | ||||||
| Depreciation | i 715,038 | i 72,342 | ||||||
| Amortization of intangible assets | i 20,906 | i 103,480 | ||||||
| Amortization of original-issue-discounts | i 224,276 | i 697,594 | ||||||
| Bad debt expense | i 2,898 | i 47,452 | ||||||
| Change in fair value of warrant liability | ( i 114,088 | ) | - | |||||
| Gain on debt extinguishment | - | ( i 196,889 | ) | |||||
| Stock-based interest expense | i 73,078 | - | ||||||
| Stock-based consulting expense | i 2,139,860 | i 417,048 | ||||||
| Changes in operating assets and liabilities: | ||||||||
| Accounts receivable | ( i 1,307,616 | ) | ( i 204,274 | ) | ||||
| Inventory | ( i 608,636 | ) | i 24,711 | |||||
| Prepaid expenses | ( i 652 | ) | i 159,328 | |||||
| Deposits | - | ( i 2,000 | ) | |||||
| Other noncurrent assets | - | i 7,347 | ||||||
| Operating lease right-of-use asset | ( i 16,486 | ) | ( i 573 | ) | ||||
| Accounts payable | i 1,573,418 | i 649,552 | ||||||
| Accrued expenses | ( i 499,847 | ) | ( i 42,885 | ) | ||||
| Net cash used in operating activities | ( i 2,356,815 | ) | ( i 3,187,638 | ) | ||||
| Investing activities: | ||||||||
| Purchase of property and equipment | - | ( i 166,476 | ) | |||||
| Purchase of intangible assets | - | ( i 177,530 | ) | |||||
| Net cash used in investing activities | - | ( i 344,006 | ) | |||||
| Financing activities: | ||||||||
| Net proceeds received from notes and loans payable | i 1,859,450 | i 1,525,000 | ||||||
| Proceeds from issuance of Series D Preferred Stock | - | i 2 | ||||||
| Proceeds from sale of common stock | i 500,000 | i 2,866,000 | ||||||
| Repayments of notes and loans payable | ( i 277,037 | ) | ( i 224,000 | ) | ||||
| Deferred financing costs | ( i 77,702 | ) | - | |||||
| Amounts received from related parties, net | i 27,161 | - | ||||||
| Net cash provided by financing activities | i 2,031,872 | i 4,167,002 | ||||||
| Decrease in cash and cash equivalents | ( i 324,943 | ) | i 635,358 | |||||
| Cash and cash equivalents, beginning of period | i 449,001 | i 457,798 | ||||||
| Cash and cash equivalents, end of period | $ | i 124,058 | $ | i 1,093,156 | ||||
| Supplemental Cash Flow Information: | ||||||||
| Income taxes paid | $ | - | $ | i 1,169 | ||||
| Interest paid | $ | i 62,100 | $ | i 4,000 | ||||
| Non-cash Investing and Financing Activities: | ||||||||
| Issuance of common stock in lieu of repayment of notes payable | $ | - | $ | i 537,748 | ||||
| Issuance of common stock in asset acquisitions | $ | i 1,767,498 | $ | i 137,673 | ||||
| Debt discount associated with warrant liability | $ | i 286,357 | $ | - | ||||
| Issuance of common stock warrants and commitment shares in connection with convertible promissory note | $ | - | $ | i 662,062 | ||||
See notes to consolidated financial statements
C:
| 6 |
Can B̅ Corp. and Subsidiaries
Notes to Consolidated Financial Statements
i
Note 1 – Organization and Description of Business
Can B̅ Corp. was originally incorporated as WrapMail, Inc. (“WRAP”) in Florida on October 11, 2005. On May 15, 2017, WRAP changed its name to Canbiola, Inc. On January 16, 2020 Canbiola, Inc. changed its name to Can B̅ Corp. (the “Company”, “we”, “us”, “our”, “CANB”, “Can B̅” or “Registrant”).
The Company acquired 100% of the membership interests in Pure Health Products, LLC, a New York limited liability company (“PHP” or “Pure Health Products”) effective December 28, 2018. The Company runs it manufacturing operations through PHP and holds and sells several of its brands through PHP as well. The Company’s durable equipment products, such as sam® units with and without CBD infused pads, are marketed and sold through its wholly-owned subsidiaries, Duramed Inc. (incorporated on November 29, 2018) and Duramed MI LLC (fka DuramedNJ, LLC) (incorporated on May 29, 2019) (collectively, “Duramed”). Duramed began operating on or about February 1, 2019. Most of the Company’s consumer products include hemp derived cannabidiol (“CBD”); however, the Company has just recently begun extracting cannabinol (“CBN”) and cannabigerol (“CBG”) for wholesale to third-parties looking to incorporate such compounds into their products through its wholly owned subsidiaries, Botanical Biotech, LLC (incorporated March 10, 2021), TN Botanicals, LLC and CO Botanicals LLC (both incorporated in August 2021). These three subsidiaries have also begun synthesizing Delta-8 and Delta-10 from hemp. Delta-8 and Delta-10 can produce similar, though less potent, effects as delta-9 (commonly referred to as THC); however, the legality of hemp derived Delta-8 and Delta-10 are in a gray area and considered a potential loophole at this point due to the 2018 hemp bill. The Company’s other subsidiaries did not have operations during the year ended December 31, 2021.
The Company is in the business of promoting health and wellness through its development, manufacture and sale of products containing cannabinoids derived from hemp biomass and the licensing of durable medical devises. Can B̅’s products include oils, creams, moisturizers, isolate, gel caps, spa products, and concentrates and lifestyle products. Can B̅ develops its own line of proprietary products as well seeks synergistic value through acquisitions in the hemp industry. Can B̅ aims to be the premier provider of the highest quality hemp derived products on the market through sourcing the best raw material and offering a variety of products we believe will improve people’s lives in a variety of areas.
i
The consolidated financial statements have been prepared on a “going concern” basis, which contemplates the realization of assets and liquidation of liabilities in a normal course of business. As of June 30, 2022, the Company had cash and cash equivalents of $ i 124,058 and negative working capital of $ i 2,205,873. For the six months ended June 30, 2022 and 2021, the Company had incurred losses of $ i 5,130,783 and $ i 4,919,871, respectively. These factors raise substantial doubt as to the Company’s ability to continue as a going concern. The Company plans to improve its financial condition by raising capital through the sale of shares of its common stock. Also, the Company plans to expand its operation of CBD products to increase its profitability. The consolidated financial statements do not include any adjustments that might be necessary should the Company be unable to continue as a going concern.
/ i
Note 3 – Basis of Presentation and Summary of Significant Accounting Policies
i
Basis of Financial Statement Presentation
The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information, and with the rules and regulations of the Securities and Exchange Commission (“SEC”) regarding interim financial reporting. Accordingly, these interim consolidated financial statements do not include all the information and footnotes required by GAAP for complete financial statements. In the opinion of the management of the Company, as defined below, these unaudited consolidated financial statements include all adjustments necessary to present fairly the information set forth therein. Results for interim periods are not necessarily indicative of results to be expected for a full year.
The consolidated balance sheet information as of December 31, 2021 was derived from the audited consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021 (“2021 Form 10-K”). The interim consolidated financial statements contained herein should be read in conjunction with the 2021 Form 10-K.
C:
| 7 |
Can B̅ Corp. and Subsidiaries
Notes to Consolidated Financial Statements
i
The unaudited consolidated financial statements contained herein include the accounts of Can B Corp. and its wholly owned subsidiaries. All significant intercompany balances and transactions have been eliminated.
i
Commencing in December 2019, the novel strain of coronavirus (“COVID-19”) began spreading throughout the world, including the first outbreak in the US in February 2020. On March 11, 2020, the World Health Organization declared COVID-19 a global pandemic and recommended containment and mitigation measures worldwide. COVID-19 has disrupted and continues to significantly disrupt local, regional, and global economies and businesses. The COVID-19 outbreak is disrupting supply chains and affecting production and sales across a range of industries. The extent of the impact of COVID-19 on the Company’s operational and financial performance will depend on certain developments, including the duration and spread of the outbreak, impact on the Company’s customers, employees and vendors, all of which are uncertain and cannot be predicted. At this point, the extent to which COVID-19 may impact the Company’s financial condition and/or results of operations is uncertain.
In response to COVID-19, the Company put into place certain restrictions, requirements and guidelines to protect the health of its employees and clients, including requiring that certain conditions be met before employees return to the Company’s offices. Also, to protect the health and safety of its employees, the Company’s daily execution has evolved into a largely virtual model. The Company plans to continue to monitor the current environment and may take further actions that may be required by federal, state or local authorities or that it determines to be in the interests of its employees, customers, and partners.
i
The preparation of financial statements and related disclosures in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses in those financial statements. Certain significant accounting policies that contain subjective management estimates and assumptions include those related to revenue recognition, inventory, goodwill, intangible assets and other long-lived assets, income taxes and deferred taxes. Descriptions of these policies are discussed in the Company’s 2021 Form 10-K. Management evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors, including the current economic environment, and adjusts when facts and circumstances dictate. As future events and their effects cannot be determined with precision, actual results could differ significantly from those estimates and assumptions. Significant changes, if any, in those estimates resulting from continuing changes in the economic environment will be reflected in the consolidated financial statements in future periods.
i
Significant Accounting Policies
The Company’s significant accounting policies are described in “Note 3: Summary of Significant Accounting Policies” of our 2021 Form 10-K.
C:
| 8 |
Can B̅ Corp. and Subsidiaries
Notes to Consolidated Financial Statements
i
As of June 30, 2022, the Company reports operating results and financial data in one operating and reportable segment. The Chief Executive Officer, who is the chief operating decision maker, manages the Company as a single profit center in order to promote collaboration, provide comprehensive service offerings across the entire customer base, and provide incentives to employees based on the success of the organization as a whole. Although certain information regarding selected products or services is discussed for purposes of promoting an understanding of the Company’s business, the chief operating decision maker manages the Company and allocates resources at the consolidated level.
i
Certain amounts in the prior year consolidated financial statements have been reclassified to conform to the current year presentation. These reclassification adjustments had no effect on the Company’s previously reported net loss.
/ i
Note 4 – Fair Value Measurements
i
The carrying value and fair value of the Company’s financial instruments are as follows:
Schedule of Carrying Value and Fair value
| June 30, 2022 | ||||||||||||||||
| Level 1 | Level 2 | Level 3 | Total | |||||||||||||
| Liabilities | ||||||||||||||||
| Warrant liabilities | $ | — | $ | — | $ | i 172,269 | $ | i 172,269 | ||||||||
| As of December 31, 2021 | ||||||||||||||||
| Level 1 | Level 2 | Level 3 | Total | |||||||||||||
| Liabilities | ||||||||||||||||
| Warrant liabilities | $ | — | $ | — | $ | — | $ | — | ||||||||
i
The fair value of the warrants outstanding was estimated using the Black-Scholes model. The application of the Black-Scholes model requires the use of a number of inputs and significant assumptions including volatility. The following reflects the inputs and assumptions used:
Schedule of Fair Value of the Warrants Outstanding
| As of | ||||||||
| 2022 | ||||||||
| Stock price | $ | N/A | ||||||
| Exercise price | $ | N/A | ||||||
| Remaining term (in years) | N/A | |||||||
| Volatility | % | N/A | ||||||
| Risk-free rate | % | N/A | ||||||
| Expected dividend yield | — | % | — | |||||
i
The warrant liabilities will be remeasured at each reporting period with changes in fair value recorded in other income (expense), net on the consolidated statements of operations. The change in fair value of the warrant liabilities was as follows:
Schedule of Change in Fair Value of the Warrant Liabilities
| Warrant liabilities | ||||
| Estimated fair value at December 31, 2021 | $ | - | ||
| Issuance of warrant liabilities | i 225,015 | |||
| Change in fair value | ( i 29,337 | ) | ||
| Estimated fair value at March 31, 2022 | $ | i 195,678 | ||
| Issuance of warrant liabilities | i 61,342 | |||
| Change in fair value | ( i 84,751 | ) | ||
| Estimated fair value at June 30, 2022 | $ | i 172,269 |
C:
| 9 |
Can B̅ Corp. and Subsidiaries
Notes to Consolidated Financial Statements
/ i
Botanical Biotech Asset Acquisition
On March 11, 2021, Company entered into an Asset Acquisition Agreement, which was fully executed on March 17, 2021, with multiple sellers (each, a “Seller” and, collectively, the “Sellers”), pursuant to which the Sellers agreed to sell certain assets to Company, and to transfer such assets to Botanical Biotech, LLC, a newly-formed, wholly-owned subsidiary of the Company (“Transferee” or “BB”). The assets purchased (“BB Assets”) include certain materials and manufacturing equipment, marketing or promotional designs, brochures, advertisements, concepts, literature, books, media rights, rights against any other person or entity in respect of any of the foregoing and all other promotional properties, in each case primarily used, developed or acquired by the Sellers for use in connection with the ownership and operation of the BB Assets. In exchange for the BB Assets the Company will pay the Seller a maximum of $ i 355,057, payable half in the form of cash or cash equivalent and half in the form of restricted shares of common stock of the Company (the “Shares”) at a price per Share equal to the average closing price of the common stock of the Company during the ten ( i 10) consecutive trading days immediately preceding the closing. The Company has agreed to indemnify the Sellers for certain breaches of covenants, representations and warranties and for claims relating to the BB Assets following closing.
In conjunction with the BB asset acquisition, the Company entered into employment agreements with two sellers.
The Company and BB entered into an employment agreement with Lebsock dated March 11, 2021 (the “Lebsock Agreement”) pursuant to which Lebsock will serve as the President of BB for a term of three (3) years. The term of the Lebsock Agreement will automatically renew for an additional 3-year term unless other terminated by either party.
Lebsock will receive a base salary equal to $ i 120,000 per year, subject to an annual increase of not less than % on each anniversary of the Lebsock Agreement during the term. The Company also agreed to issue a stock bonus to Lebsock in accordance with the Company’s Incentive Stock Option Plan (“ISOP”) in an amount of $ i 100,000, and to pay Lebsock a defined percentage of the EBITDA for BB each calendar quarter (“Profit Split”) according to a mutually agreed performance target (“Target”). EBITDA is defined as the earnings before interest, depreciation, taxes, depreciation, and amortization and will be paid as reported by the Company’s accountant and as reviewed by the Company’s auditor. It will be accumulative on a quarter-to-quarter basis, meaning if one quarter has a negative EBITDA, it would be offset against the following quarter’s positive EBITDA distribution. Lebsock has the option to accept the Profit Split in either direct cash payment or Shares, or any combination, at Lebsock’s option. Shares would be valued at the prior 10-day closing price and issued under SEC Rule 144 restriction.
Effective March 16, 2021, BB entered into a Consulting Agreement (the “Schlosser Agreement”) with Schlosser pursuant to which Schlosser has agreed to provide consulting services to BB for a period of 3 months in exchange for compensation equal to $ i 10,000 per month. Schlosser will also be entitled to reimbursement for certain work-related expenses. Pursuant to the Schlosser Agreement, Schlosser also agreed to assign to BB all inventions developed by Schlosser in connection with his services to BB. The Schlosser Agreement also contains certain non-compete and confidentiality provisions. Per the Acquisition Agreement, Schlosser was to receive an employment agreement similar to the Lebsock Agreement; however, BB and Schlosser elected to enter into the Schlosser Agreement instead.
CO Botanicals Asset Acquisition
On August 12, 2021, The Company and CO Botanicals LLC (“COB”), a newly-formed, wholly-owned subsidiary of the Company entered into an Equipment Acquisition Agreement (the “TWS Agreement”) with TWS Pharma, LLC,
(“TWS Pharma”) and L7 TWS Pharma, LLC (“L7 TWS” and, collectively with TWS Pharma, “TWS”). Pursuant to the TWS Agreement, COB agreed to purchase certain equipment and other assets from TWS (the “TWS Assets”) for a total purchase price equal to $ i 5,316,774, with $ i 1,250,000 payable via a 12-month promissory note issued by the Company to TWS Pharma with i 6% simple interest and monthly payments of $ i 100,000 due per month (the “TWS Note”), and $ i 4,066,774 payable in shares of the Company’s common stock valued at $ per share (the “TWS Shares”); provided, however, i that $1,750,000 of the TWS Shares will be withheld in escrow for a period of ninety (90) days from the closing date, which will be deducted from the purchase price should the Company discover any defects or misrepresentations. The first $500,000 of payments of the TWS Note will be secured by 1,000,000 shares of the Company’s common stock to be held in escrow. During the six months ending June 30, 2022, the $1,750,000 of shares held in escrow were released and issued.
C:
| 10 |
Can B̅ Corp. and Subsidiaries
Notes to Consolidated Financial Statements
TN Botanicals Asset Acquisition
On August 13, 2021 the Company and TN Botanicals LLC (“TNB”), a newly-formed, wholly-owned subsidiary of the Company, entered into an Asset Purchase Agreement (the “MCB Agreement”) with Music City Botanicals, LLC, pursuant to which TNB agreed to purchase certain equipment, other assets, and intellectual property from MCB (the “MCB Assets”) for a total purchase price equal to $ i 1,394,324, with $ i 498,259 payable in cash and $ i 896,065 payable in shares of the Company’s common stock valued at $ per share (the “MCB Shares”).
Imbibe Health Solutions Asset Acquisition
On February 22, 2021, Can B̅ Corp. (the “Company”) entered into a material definitive agreement (“Acquisition Agreement”) with Imbibe Health Solutions, LLC, a Delaware limited liability company (“Imbibe”), pursuant to which Imbibe agreed to sell certain of its assets to the Company. The assets to be purchased (“Assets”) include the intellectual property rights and other intangible assets relating to its branded products containing CBD. In exchange for the Assets, the Company has agreed to pay Imbibe $ i 120,000 in the form of shares of common stock of the Company (with standard restricted legend, the “Shares”) at a price per share equal to the average price of the common stock of the Company during the ten (10) consecutive trading days immediately preceding the closing. The transaction finalized and $102,502 worth of shares were issued on November 7, 2021 and the remaining balance of $17,498 of shares were issued during the six months ending June 30, 2022.
/ i
i
Inventories consist of:
| June 30, | December 31, | |||||||
| 2022 | 2021 | |||||||
| Raw materials | $ | i 836,399 | $ | i 818,042 | ||||
| Finished goods | i 2,325,675 | i 1,735,396 | ||||||
| Total | $ | i 3,162,074 | $ | i 2,553,438 | ||||
/ i
Note 7 – Property and Equipment
i
Property and equipment consist of:
Summary of Property, Plant and Equipment
| June 30, | December 31, | |||||||
| 2022 | 2021 | |||||||
| Furniture and fixtures | $ | i 21,724 | $ | i 21,724 | ||||
| Office equipment | i 12,378 | i 12,378 | ||||||
| Manufacturing equipment | i 7,117,188 | i 7,018,522 | ||||||
| Medical equipment | i 776,396 | i 776,396 | ||||||
| Leasehold improvements | i 26,902 | i 26,902 | ||||||
| Total | i 7,954,588 | i 7,855,922 | ||||||
| Accumulated depreciation | ( i 1,520,208 | ) | ( i 802,996 | ) | ||||
| Net | $ | i 6,434,380 | $ | i 7,052,926 | ||||
Depreciation expense related to property and equipment was $ i 715,038 and $ i 72,342 for the six-month periods ending June 30, 2022 and 2021, respectively.
/ i
i
Intangible assets consist of:
| June 30, | December 31, | |||||||
| 2022 | 2021 | |||||||
| Technology, IP and patents | $ | i 435,500 | $ | i 418,003 | ||||
| Total | i 435,500 | i 418,003 | ||||||
| Accumulated amortization | ( i 69,894 | ) | ( i 48,988 | ) | ||||
| Intangible assets, net | $ | i 365,606 | $ | i 369,015 | ||||
Amortization expense was $ i 20,906 and $ i 103,480 for the six months ended June 30, 2022 and 2021, respectively.
C:
| 11 |
Can B̅ Corp. and Subsidiaries
Notes to Consolidated Financial Statements
i
Amortization expense for the balance of 2022, and for each of the next five years and thereafter is estimated to be as follows:
Schedule of Estimated Amortization Expenses
| Six months ended December 31, 2022 | $ | i 21,760 | ||
| Fiscal year 2023 | i 43,520 | |||
| Fiscal year 2024 | i 43,520 | |||
| Fiscal year 2025 | i 43,520 | |||
| Fiscal year 2026 | i 43,520 | |||
| Thereafter | i 169,766 | |||
| Intangible assets, net | $ | i 365,606 |
/ i
Note 9 – Notes and Loans Payable
Convertible Promissory Notes
In December 2020, the Company entered into a convertible promissory note (“ASOP Note I”) with Arena Special Opportunities Partners I, LP (“ASOP”). The principal balance of the note is $ i 2,675,239 and it is to be utilized for working capital purposes. The note matures on i January 31, 2022 and all principal, accrued and unpaid interest is due at maturity at a rate of i 12% per annum. The conversion options contained in the convertible promissory note were evaluated for derivative accounting under ASC 815, Derivatives and Hedging, and determined not to be considered a derivative and therefore has been recorded in liabilities as part of the convertible promissory note and not bifurcated. In addition, the ASOP convertible promissory note was issued with common stock warrants. The common stock purchase warrants entitle the holder to purchase an aggregate of up to i 3,426,280 shares of the Company’s common stock at an exercise price of $ i 0.45 per share. The common stock purchase warrants issued to ASOP are considered derivatives, but satisfied the criteria for classification as equity instruments, and were bifurcated from the host contract - convertible promissory note and recorded in equity at their relative fair values with a corresponding debt discount recorded to ASOP Note I. The principal balance outstanding at June 30, 2022 was $ i 2,400,997.
In December 2020, the Company entered into a convertible promissory note (“ASOF Note I”) with Arena Special Opportunities Fund, LP (“ASOF”). The principal balance of the note is $ i 102,539 and it is to be utilized for working capital purposes. The note matures on i January 31, 2022 and all principal, accrued and unpaid interest is due at maturity at a rate of i 12% per annum. The conversion options contained in the convertible promissory note were evaluated for derivative accounting under ASC 815, Derivatives and Hedging, and determined not to be considered a derivative and therefore has been recorded in liabilities as part of the convertible promissory note and not bifurcated. In addition, the ASOF convertible promissory note was issued with common stock warrants. The common stock purchase warrants entitle the holder to purchase an aggregate of up to i 131,325 shares of the Company’s common stock at an exercise price of $ i 0.45 per share. The common stock purchase warrants issued to ASOF are considered derivatives, but satisfied the criteria for classification as equity instruments, and were bifurcated from the host contract - convertible promissory note and recorded in equity at their relative fair values with a corresponding debt discount recorded to ASOF Note I. The principal balance outstanding at June 30, 2022 was $ i 87,773.
In May 2021, the Company entered into a convertible promissory note (“ASOP Note II”) with Arena Special Opportunities Partners I, LP. The principal balance of the note is $ i 1,193,135 and it is to be utilized for working capital purposes. The note matures on i January 31, 2022 and all principal, accrued and unpaid interest is due at maturity at a rate of i 12% per annum. The conversion options contained in the convertible promissory note were evaluated for derivative accounting under ASC 815, Derivatives and Hedging, and determined not to be considered a derivative and therefore has been recorded in liabilities as part of the convertible promissory note and not bifurcated. In addition, the ASOP convertible promissory note was issued with common stock warrants. The common stock purchase warrants entitle the holder to purchase an aggregate of up to i 1,529,670 shares of the Company’s common stock at an exercise price of $ i 0.45 per share. The common stock purchase warrants issued to ASOP are considered derivatives, but satisfied the criteria for classification as equity instruments, and were bifurcated from the host contract - convertible promissory note and recorded in equity at their relative fair values with a corresponding debt discount recorded to ASOP Note II. The principal balance outstanding at June 30, 2022 was $ i 1,073,250.
C:
| 12 |
Can B̅ Corp. and Subsidiaries
Notes to Consolidated Financial Statements
In May 2021, the Company entered into a convertible promissory note (“ASOF Note II”) with Arena Special Opportunities Fund, LP. The principal balance of the note is $ i 306,865 and it is to be utilized for working capital purposes. The note matures on i January 31, 2022 and all principal, accrued and unpaid interest is due at maturity at a rate of i 12% per annum. The conversion options contained in the convertible promissory note were evaluated for derivative accounting under ASC 815, Derivatives and Hedging, and determined not to be considered a derivative and therefore has been recorded in liabilities as part of the convertible promissory note and not bifurcated. In addition, the ASOP convertible promissory note was issued with common stock warrants. The common stock purchase warrants entitle the holder to purchase an aggregate of up to i 393,417 shares of the Company’s common stock at an exercise price of $ i 0.45 per share. The common stock purchase warrants issued to ASOF are considered derivatives, but satisfied the criteria for classification as equity instruments, and were bifurcated from the host contract - convertible promissory note and recorded in equity at their relative fair values with a corresponding debt discount recorded to ASOF Note II. The principal balance outstanding at June 30, 2022 was $ i 276,750.
The maturity dates for the above notes were extended to i April 30, 2022 on April 14, 2022 in exchange for the Company’s promise to pay the holders $ i 300,000. i The holders agreed to allow the Company to extend the notes for two additional 30-day periods for $100,000 per extension. The holders also waived certain defaults under the notes. i The Company has since elected to extend the maturity date to May 31, 2022 for the promise to pay an additional $100,000. The Company is currently in discussions regarding the further extension of the notes.
In February 2022, the Company entered into a convertible promissory note (“Tysadco Note”) with Tysadco Partners, LLC (“Tysadco”). The principal balance of the note is $ i 450,000 and it is to be utilized for working capital purposes. The note matures on i July 25, 2022 and all principal, accrued and unpaid interest is due at maturity at a rate of i 12% per annum. The conversion options contained in the convertible promissory note were evaluated for derivative accounting under ASC 815, Derivatives and Hedging, and determined not to be considered a derivative and therefore has been recorded in liabilities as part of the convertible promissory note and not bifurcated. The principal balance outstanding at June 30, 2022 was $ i 450,000. This note has been extended an additional 6 months by mutual consent for the additional consideration of issuance of twenty thousand shares of common stock.
In June 2022, the Company entered into a convertible promissory note (“Tysadco Note”) with Tysadco Partners, LLC (“Tysadco”). The principal balance of the note is $ i 75,000 and it is to be utilized for working capital purposes. The note matures on i December 7, 2022, and all principal, accrued and unpaid interest is due at maturity at a rate of i 12% per annum. The conversion options contained in the convertible promissory note were evaluated for derivative accounting under ASC 815, Derivatives and Hedging, and determined not to be considered a derivative and therefore has been recorded in liabilities as part of the convertible promissory note and not bifurcated. The principal balance outstanding at June 30, 2022 was $ i 75,000.
In March 2022, the Company entered into a convertible promissory note (“BL Note”) with Blue Lake Partners, LLC (“BL”). The principal balance of the note is $ i 250,000 and it is to be utilized for working capital purposes. The note matures on i March 22, 2023 and all principal, accrued and unpaid interest is due at maturity at a rate of i 12% per annum. The conversion options contained in the convertible promissory note were evaluated for derivative accounting under ASC 815, Derivatives and Hedging, and determined not to be considered a derivative and therefore has been recorded in liabilities as part of the convertible promissory note and not bifurcated. In addition, the BL Note was issued with common stock warrants. The common stock purchase warrants entitle the holder to purchase an aggregate of up to i 39,062 shares of the Company’s common stock at an exercise price of $ i 6.40 per share. The common stock purchase warrants issued to BL are considered derivatives and did not satisfy the criteria for classification as equity instruments and were bifurcated from the host contract - convertible promissory note and recorded as a liability at fair value with a corresponding debt discount recorded to the BL Note with subsequent changes in fair values recognized in the consolidated statement of operations at each reporting date. Aggregate amortization of the original issue discount for the six months ended, 2022 and 2021 was approximately $ i 25,500 and $ i 0, respectively. The principal balance outstanding at June 30, 2022 was $ i 250,000.
In March 2022, the Company entered into a convertible promissory note (“MH Note”) with Mast Hill Fund, LP (“MH”). The principal balance of the note is $ i 350,000 and it is to be utilized for working capital purposes. The note matures on i March 22, 2023 and all principal, accrued and unpaid interest is due at maturity at a rate of i 12% per annum. The conversion options contained in the convertible promissory note were evaluated for derivative accounting under ASC 815, Derivatives and Hedging, and determined not to be considered a derivative and therefore has been recorded in liabilities as part of the convertible promissory note and not bifurcated. In addition, the MH Note was issued with common stock warrants. The common stock purchase warrants entitle the holder to purchase an aggregate of up to i 39,062 shares of the Company’s common stock at an exercise price of $ i 6.40 per share. The common stock purchase warrants issued to MH are considered derivatives and did not satisfy the criteria for classification as equity instruments and were bifurcated from the host contract - convertible promissory note and recorded as a liability at fair value with a corresponding debt discount recorded to the MH Note with subsequent changes in fair values recognized in the consolidated statement of operations at each reporting date. Aggregate amortization of the original issue discount for the six months ended June 30, 2022 and 2021 was approximately $ i 33,800 and $ i 0, respectively. The principal balance outstanding at June 30, 2022 was $ i 350,000.
C:
| 13 |
Can B̅ Corp. and Subsidiaries
Notes to Consolidated Financial Statements
In April 2022, the Company entered into a convertible promissory note (“FM Note”) with Fourth Man, LLC (“FM”). The principal balance of the note is $ i 150,000 and it is to be utilized for working capital purposes. The note matures on i April 22, 2023 and all principal, accrued and unpaid interest is due at maturity at a rate of i 12% per annum. The conversion options contained in the convertible promissory note were evaluated for derivative accounting under ASC 815, Derivatives and Hedging, and determined not to be considered derivatives and therefore have been recorded in liabilities as part of the convertible promissory note and not bifurcated. In addition, the FM Note was issued with common stock warrants. The common stock purchase warrants entitle the holder to purchase an aggregate of up to i 23,437 shares of the Company’s common stock at an exercise price of $ i 6.40 per share. The common stock purchase warrants issued to FM are considered derivatives and did not satisfy the criteria for classification as equity instruments and were bifurcated from the host contract - convertible promissory note and recorded as a liability at fair value with a corresponding debt discount recorded to the FM Note with subsequent changes in fair values recognized in the consolidated statement of operations at each reporting date. Aggregate amortization of the original issue discount for the period ended June 30, 2022 and 2021 was approximately $ i 10,700 and $ i 0, respectively. The principal balance outstanding at June 30, 2022 was $ i 150,000.
In June 2022, the Company entered into a convertible promissory note (“Alumni Note”) with Alumni Capital, LP (“Alumni”). The principal balance of the note is $ i 62,500 and it is to be utilized for working capital purposes. The note matures on i June 6, 2023 and all principal, accrued and unpaid interest is due at maturity at a rate of i 12% per annum. The conversion options contained in the convertible promissory note were evaluated for derivative accounting under ASC 815, Derivatives and Hedging, and determined not to be considered derivatives and therefore have been recorded in liabilities as part of the convertible promissory note and not bifurcated. In addition, the Alumni Note was issued with common stock warrants. The common stock purchase warrants entitle the holder to purchase an aggregate of up to i 9,766 shares of the Company’s common stock at an exercise price of $ i 6.40 per share. The common stock purchase warrants issued to Alumni are considered derivatives and did not satisfy the criteria for classification as equity instruments and were bifurcated from the host contract - convertible promissory note and recorded as a liability at fair value with a corresponding debt discount recorded to the Alumni Note with subsequent changes in fair values recognized in the consolidated statement of operations at each reporting date. Aggregate amortization of the original issue discount for the period ended June 30, 2022 and 2021 was approximately $ i 1,500 and $ i 0, respectively. The principal balance outstanding at June 30, 2022 was $ i 62,500.
In June 2022, the Company entered into a convertible promissory note (“Tysadco Note II”) with Tysadco Partners, LLC. The principal balance of the note is $ i 75,000 and it is to be utilized for working capital purposes. The note matures on i December 7, 2022 and all principal, accrued and unpaid interest is due at maturity at a rate of i 12% per annum. The conversion options contained in the convertible promissory note were evaluated for derivative accounting under ASC 815, Derivatives and Hedging, and determined not to be considered derivatives and therefore have been recorded in liabilities as part of the convertible promissory note and not bifurcated. The Tysadco Note II is convertible into common stock of the Company at any time prior to the maturity date at a conversion price of the lesser of $ i 7.50 and i 75% of the lowest daily volume weighted average price (“VWAP”) over the previous ten trading days prior to conversion. The principal balance outstanding at June 30, 2022 was $ i 75,000.
TWS Note
On August 12, 2021, pursuant to an Equipment Acquisition Agreement, the Company entered into a twelve-month promissory note of $ i 1,250,000 with payments of $ i 100,000 per month and interest at i 6% (See Note 5). As of June 30, 2022, the total amount outstanding was $ i 1,050,000.
Other Loans
On November 18, 2021, the Company entered into a $ i 100,000 unsecured promissory note agreement with a lender. The promissory note accrues interest at a rate of i 10% per annum and is due within twelve months or due on demand subsequently to any major funding received by the Company in excess of $ i 3,000,000. As of June 30, 2022 the total amount outstanding was $ i 100,000.
On February 2, 2022, the Company entered into a Future Receivable Sale and Purchase Agreement with a Purchaser. Pursuant to the terms of the agreement, the Company sold an aggregate of $ i 136,000 of future receivables for a purchase amount of $ i 100,000. The aggregate principal amount is payable in weekly installments totaling i 2,833 until such time the obligation is fully satisfied. As of June 30, 2022 the total amount outstanding was $ i 45,489.
On February 11, 2022, the Company entered into a $ i 150,000 unsecured promissory note agreement with a lender. The promissory note accrues interest at a rate of i 16% per annum and is due within six months or due on demand subsequently to any major funding received by the Company in excess of $ i 2,000,000. As of June 30, 2022 the total amount outstanding was $ i 150,000.
On March 3, 2022, the Company entered into a Receivable Purchase and Sale Agreement with a Buyer. Pursuant to the terms of the agreement, the Company sold an aggregate of $ i 350,00 of future receivables for a purchase amount of $ i 250,000. The aggregate principal amount is payable in daily installments totaling $ i 2,917 until such time the obligation is fully satisfied. As of June 30, 2022 the total amount outstanding was $ i 24,666.
On May 25, 2022, the Company entered into a Future Receivable Sale and Purchase Agreement with a Purchaser. Pursuant to the terms of the agreement, the Company sold an aggregate of $ i 54,000 of future receivables for a purchase amount of $ i 38,000. The aggregate principal amount is payable in weekly installments totaling $ i 453 until such time the obligation is fully satisfied. As of June 30, 2022 the total amount outstanding was $ i 28,308.
/ i
Note 10 – Stockholders’ Equity
Preferred Stock
i Each share of Series A Preferred Stock is convertible into 218 shares of CANB common stock and is entitled to votes. / All Preferred Shares shall rank senior to all shares of Common Stock of the Company with respect to liquidation preferences and shall rank pari passu to all current and future series of preferred stock, unless otherwise stated in the certificate of designation for such preferred stock. In the event of a Liquidation Event, whether voluntary or involuntary, each holder may elect (i) to receive, in preference to the holders of Common Stock, a one-time liquidation preference on a per-share amount equal to the per-share value of preferred shares on the issuance date, as recorded in the Company’s financial records, or (ii) to participate pari passu with the Common Stock on an as-converted basis. Subject to any adjustments, the Series A holders shall be entitled to receive such dividends paid and distributions made to the holders of shares of Common Stock on an as converted basis. During the six months ended June 30, 2022, the Company converted shares of Series A preferred stock to shares of common stock.
C:
| 14 |
Can B̅ Corp. and Subsidiaries
Notes to Consolidated Financial Statements
i Each share of Series B Preferred Stock has the first preference to dividends, distributions and payments upon liquidation, dissolution and winding-up of the Company, and is entitled to an accrued cumulative but not compounding dividend at the rate of 5% per annum whether or not declared. After six months of the issuance date, such share and any accrued but unpaid dividends can be converted into common stock at the conversion price which is the lower of (i) $0.0101; or (ii) the lower of the dollar volume weighted average price of CANB common stock on the trading day prior to the conversion day or the dollar volume weighted average price of CANB common stock on the conversion day. i The shares of Series B Preferred Stock have no voting rights.
Each share of Series C Preferred Stock has preference to payment of dividends, if and when declared by the Company, compared to shares of our common stock. Each Preferred Series C share is convertible into shares of common stock. The shares of Series C Preferred Stock have voting rights as if fully converted.
i Each share of Series D Preferred Stock has 10,000 shares of voting rights only pari passu to common shares voting with no conversion rights and no equity participation. The Company can redeem Series D Preferred Stock at any time for par value.
On February 8, 2021, the Company’s Board of Directors approved the designation of the Series D Preferred Shares and the number of shares constituting such series, and the rights, powers, preferences, privileges and restrictions relating to such series. On March 27, 2021, the Company filed an amendment to its articles of incorporation to authorize shares of a new Series D Preferred Stock with a par value of $ each. All Series D Preferred Shares shall rank senior to all shares of Common Stock of the Company with respect to liquidation preferences and shall rank pari passu to all current and future series of preferred stock, unless otherwise stated in the certificate of designation for such preferred stock. i Each Series D Preferred Share shall have voting rights equal to 667 shares of Common Stock, adjustable at any recapitalization of the Company’s stock. In the event of a liquidation event, whether voluntary or involuntary, each holder shall have a liquidation preference on a per-share amount equal to the par value of such holder’s Series D Preferred Shares. The holders shall not be entitled to receive distributions made or dividends paid to the Company’s other stockholders. Except as otherwise required by law, for as long as any Series D Preferred Shares remain outstanding, the Company shall have the option to redeem any outstanding share of Series D Preferred Shares at any time for a purchase price of par value per share of Series D Preferred Shares (“Price per Share”). Should the Company desire to purchase Series D Preferred Shares, the Company shall provide the Holder with written notice and a check or cash in an amount equal to the number of shares of Series D Preferred Shares being purchased multiplied by the Price per Share. The shares of Series D Preferred Shares so purchased shall be deemed automatically cancelled and the Holder shall return the certificates for such share to the Corporation. On or around March 27, 2021, the Company issued Mr. Alfonsi, Mr. Ferro, and Mr. Teeple Series D Preferred Stock in the amount of shares each and to COO Philip Scala in the amount of shares, i collectively representing 1,300,000 voting shares.
Common Stock
For the six months ended June 30, 2022, the Company issued an aggregate of shares of Common Stock under its Offering Statement on Form 1-A (File No. 024-11233) (the “Regulation A Offering”).
In addition, for the six months ended June 30, 2022, the Company issued an aggregate of , i 13,704, , and of Common Stock for asset acquisitions, property and equipment, services rendered, and in lieu of interest repayments, respectively.
C:
| 15 |
Can B̅ Corp. and Subsidiaries
Notes to Consolidated Financial Statements
/ i
i
Summary of Stock Options Activity
| Option Shares | Weighted Average Exercise Price | Weighted Average Remaining Contractual Life (Years) | ||||||||||
| Outstanding, January 1, 2022 | i 377,654 | $ | i 6.11 | |||||||||
| Granted | i 79,013 | i 5.10 | ||||||||||
| Exercised | - | - | - | |||||||||
| Forfeited | - | - | - | |||||||||
| Expired | - | - | - | |||||||||
| Outstanding, June 30, 2022 | i 456,666 | $ | i 5.93 | |||||||||
i
| Option Shares | Weighted Average Grant-Date Fair Value | |||||||
| Non-vested options, January 1, 2022 | - | $ | - | |||||
| Granted | i 79,012 | i 7.24 | ||||||
| Vested | ( i 79,012 | ) | i 7.24 | |||||
| Forfeited | - | - | ||||||
| Non-vested options, June 30, 2022 | - | $ | - | |||||
/ / i
The Company’s income tax provisions for the six months ended June 30, 2022 and 2021 reflect the Company’s estimates of the effective rates expected to be applicable for the respective full years, adjusted for any discrete events, which are recorded in the period that they occur. These estimates are reevaluated each quarter based on the Company’s estimated tax expense for the full year. The estimated effective tax rate includes the impact of valuation allowances in various jurisdictions.
i
Note 13 – Related Party Transactions
For the six months ended June 30, 2022 and 2021, the Company incurred fees to a service provider that is a relative of a director for professional services in the amount of $ i 8,000 and $ i 9,900, respectively. At June 30, 2022 and December 31, 2021, the Company had outstanding payables to the aforementioned service provider of $ i 8,000 and $ i 5,000, respectively.
At June 30, 2022, the Company has amounts due to a director of the Company of approximately $ i 245,434 which are expected to be repaid in the next twelve months.
C:
| 16 |
Can B̅ Corp. and Subsidiaries
Notes to Consolidated Financial Statements
/ i
Note 14 – Commitments and Contingencies
Lease Agreements
The Company leases office space in numerous medical facilities offices under month-to-month agreements.
Rent expense for the six months ended June 30, 2022 and 2021 was $ i 332,520 and $ i 84,724, respectively.
i
At June 30, 2022, the future minimum lease payments under non-cancellable operating leases were:
Schedule of Future Minimum Lease Payments Under Non-cancellable Operating Leases
| Six months ended December 31, 2022 | $ | i 614,600 | ||
| Fiscal year 2023 | i 832,893 | |||
| Fiscal year 2024 | i 326,974 | |||
| Total | $ | i 1,774,467 |
/ i
The Company evaluates subsequent events and transactions that occur after the balance sheet date up to the date that the condensed consolidated financial statements are issued and as of that date, except as reported below, there were no subsequent events that required adjustment or disclosure in the consolidated financial statements.
On July 18, 2022, Imbibe Wellness Solutions, LLC (“Imbibe”), a subsidiary of Can B Corp., a Florida corporation (the “Company”), entered into a definitive agreement (the “Agreement”) with Forever Brands, inc. (“Forever Brands”) for Imbibe to be the exclusive manufacturer, distributor, and direct to consumer seller of certain super food and related nutritional products to be marketed under the Longevity by Brooke Burke trademarks and brand.
Imbibe will engage Pure Health Products, LLC (“PHP”), another subsidiary of the Company, to produce the products under a non-exclusive Private Label Manufacturing Agreement whereby PHP manufactures and ships products directly to Forever Brand’s customers. Forever Brands has entered into an Endorsement Agreement with Brooke Burke and her company, BB Body, Inc. to market, endorse and promote the products in a monthly, online subscription model.
On August 5, 2022, the Company entered into an unsecured promissory note agreement with a lender. The promissory note accrues interest at a rate of i 16% per annum and is due within three months or due on demand subsequently to any major funding received by the Company in excess of $ i 350,000. At any time after three months from funding date, until this Promissory Note is paid, Lender may collect directly from the Can B Corp. accounts receivables collections for the full amount of principal and interest due.
Effective August 12, 2022, reference is hereby made to that certain engagement agreement (the “Agreement”), dated as of October 7, 2021, as amended on February 11, 2022, by and between Can B Corp. (the “Company”) and H.C. Wainwright & Co., LLC (“Wainwright”), pursuant to which Wainwright shall act as the exclusive agent, advisor or underwriter in any Offering of Securities of the Company during the Term. Defined terms used herein but not defined herein shall have the meanings ascribed to such terms in the Agreement. At the Company’s request, Wainwright hereby agrees to voluntarily terminate the Agreement as of August 12, 2022.
/C:
| 17 |
ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
Can B̅ Corp. was originally incorporated as WrapMail, Inc. (“WRAP”) in Florida on October 11, 2005. On May 15, 2017, WRAP changed its name to Canbiola, Inc. On January 16, 2020 Canbiola, Inc. changed its name to Can B̅ Corp. (.
The Company acquired 100% of the membership interests in Pure Health Products, LLC, a New York limited liability company (“PHP” or “Pure Health Products”) effective December 28, 2018. The Company runs it manufacturing operations through PHP and holds and sells several of its brands through PHP as well. The Company’s durable equipment products, such as sam® units with and without CBD infused pads, are marketed and sold through its wholly-owned subsidiaries, Duramed Inc. (incorporated on November 29, 2018) and Duramed MI LLC (fka DuramedNJ, LLC) (incorporated on May 29, 2019) (collectively, “Duramed”). Duramed began operating on or about February 1, 2019. Most of the Company’s consumer products include hemp derived cannabidiol (“CBD”); however, the Company has just recently begun extracting cannabinol (“CBN”) and cannabigerol (“CBG”) for wholesale to third-parties looking to incorporate such compounds into their products through its wholly owned subsidiaries, Botanical Biotech, LLC (incorporated March 10, 2021) and TN Botanicals LLC and CO Botanicals LLC (both incorporated in August 2021). The three subsidiaries have also begun synthesizing Delta-8 and Delta-10 from hemp. Delta-8 can produce similar, though less potent, effects as delta-9 (commonly referred to as THC); however, the legality of hemp derived delta-8 is in a gray area. The Company’s other subsidiaries did not have operations during the six months ended June 30, 2022.
The Company is in the business of promoting health and wellness through its development, manufacture and sale of products containing cannabinoids derived from hemp biomass and the licensing of durable medical devises. Can B̅’s products include oils, creams, moisturizers, isolate, gel caps, spa products, and concentrates and lifestyle products. Can B̅ develops its own line of proprietary products as well seeks synergistic value through acquisitions in the hemp industry. Can B̅ aims to be the premier provider of the highest quality hemp derived products on the market through sourcing the best raw material and offering a variety of products we believe will improve people’s lives in a variety of areas.
The consolidated financial statements include the accounts of CANB and its operational wholly owned subsidiaries.
Results of Operations
Three months ended June 30, 2022 compared to three months ended June 30, 2021.
Revenues increased $869,236 from $401,766 in 2021 to $1,271,002 in 2022. The increase is due to the wind down of restrictions related to the Covid-19 Pandemic surrounding elective surgeries, enabling an increase in the usage of the Company’s Duramed product lines and ultrasound device associated with patient recovery. Additionally, due to asset acquisitions in 2021, the Company’s Music City Botanical and Botanical Biotech brands related to an increase of sales compared to 2021 of approximately $746,000.
Cost of product sales increased $772,205 from $258,612 in 2021 to $1,030,817 in 2022 due to the increase in sales caused by increase in operations and 2021 acquisitions.
Operating expenses decreased $930,204 from $2,728,998 in 2021 to $1,798,794 in 2022 as a direct result of 2021 professional fees incurred and attributable to the Company’s asset acquisitions and Regulation A offering in the six months ending June 30, 2021.
Net loss decreased 1,094,103 from $2,739,989 in 2021 to $1,645,886 in 2022. The decrease was due to the $930,204 decrease in total operating expenses coupled by the $97,031 increase in gross profit.
Six months ended June 30, 2022 compared to six months ended June 30, 2021.
Revenues increased 1,619,861 from $605,796 in 2021 to $3,131,322 in 2022. The increase is due to the wind down of restrictions related to the Covid-19 Pandemic surrounding elective surgeries, enabling an increase in the usage of the Company’s Duramed product lines and ultrasound device associated with patient recovery. Additionally, due to asset acquisitions in 2021, the Company’s Music City Botanical and Botanical Biotech brands related to an increase of sales compared to 2021 of $1,310,996.
Cost of product sales increased $1,885,740 from $335,407 in 2021 to $2,221,147 in 2022 due to the increase in sales caused by increase in operations and 2021 acquisitions.
Operating expenses increased $909,114 from $4,751,667 in 2021 to $5,660,791 in 2022 due to accounting, legal, and other professional fees related to the Company’s registration statement S-1 filing efforts during the first quarter of 2022.
Net loss increased 210,912 from $4,919,871 in 2021 to $5,130,783 in 2022. The increase was due to continued efforts and fees related to the Company’s registration statement S-1 filings during the first quarter of 2022.
C:
| 18 |
Liquidity and Capital Resources
At June 30, 2022, the Company had cash and cash equivalents of $124,058 and negative working capital of $2,205,873. Cash and cash equivalents decreased $324,943 from $449,001 at December 31, 2021 to $124,058 at June 30, 2022. For the six months ended June 30, 2022, $2,031,872 was provided by financing activities, $2,356,815 was used in operating activities, and $0 was used in investing activities.
The Company currently has no agreements, arrangements or understandings with any person to obtain funds through bank loans, lines of credit or any other sources.
We have no off-balance sheet arrangements.
Trend Information
The novel coronavirus disease of 2019 (“COVID-19”) outbreak has affected the Company’s operations as set forth above. The full impact of the COVID-19 outbreak continues to evolve. As such, it is uncertain as to the full magnitude that the pandemic will have on our financial condition, liquidity, and future results of operations. Management is actively monitoring the impact of the global situation on our financial condition, liquidity, operations, suppliers, industry, and workforce. Given the daily evolution of the COVID-19 outbreak and the global responses to curb its spread, we are not able to estimate the effects of the COVID-19 outbreak on our results of operations, financial condition, or liquidity for the foreseeable future. Presently, our Duramed operations are at 80% of pre-COVID operational level. Our expectation that as business open, and in particular medical offices, that our recovery will progress in sync with the speed of the business openings and expect to be back to pre-COVID operational level by end of the 2nd quarter 2022. Sales of CBD and related products continue to moderately recover and we expect to be back at pre-COVID levels by the end of the 3rd quarter 2022.
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
None.
ITEM 4. CONTROLS AND PROCEDURES
(A) EVALUATION OF DISCLOSURE CONTROLS AND PROCEDURES
As of June 30, 2022, our principal executive officer and principal financial officer conducted an evaluation regarding the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) or 15d-15(e) under the Exchange Act). Based upon the evaluation of these controls and procedures, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures were not effective as of the end of the period covered by this report.
(B) CHANGES IN INTERNAL CONTROL OVER FINANCIAL REPORTING
There were no changes in our internal control over financial reporting in our fiscal quarter for the period June 30, 2022 covered by this Quarterly Report on Form 10-Q, that have materially affected, or are reasonably likely to materially affect our internal control over financial reporting.
C:
| 19 |
On April 28, 2021, the Company was served with a commercial legal action against the Company and certain officers by David Weissberg and Donna Marino, who are investors in the Company (collectively, the “Investors”). The complaint was filed in the Supreme Court of the State of New York, County of Nassau, Index No. 605191/2021. The complaint alleges four causes of action.
The first cause of action alleges that the Company breached Securities Purchase Agreements with the Investors by failing to assist the Investors in getting opinion letters to remove the restrictive legends from their shares, even though the Company made introductions and requests to the Company’s counsel, provided supporting documents for the Investor’s shares, and ultimately the opinion letters could not be rendered because the Investors failed to submit required documentation to counsel.
The second cause of action is similar to the first but related to alleged misrepresentations regarding removing the restrictive legends from shares that were issued for services rather than purchased.
The third cause of action alleges that the Company mislead the Investors to invest $500,000. The final cause of action alleges that officers of the Company made misrepresentations regarding the value of the Company’s stock, which caused David Weissberg to owe more in taxes than he was expecting.
Around November 24, 2021, a vendor of the Company filed amended suit against the Company in Florida, Case No. 2021 CA 001797, for monies allegedly owed and civil theft relating to such monies and related products and fraud in the inducement. We do not believe we owe such vendor any amount. The court has entered a default judgement against the Company for our failure to timely answer the complaint, which default has since been overturned.
Other than above, we are not aware of any pending or threatened legal proceedings in which we are involved.
As a smaller reporting company, we are not required to provide risk factors in this Form 10-Q, however The Company has been directly impacted and has experienced moderate interruption during this challenging COVID-19 pandemic. In accordance with applicable federal and state guidelines, the Company has implemented and prioritized strict social distancing measures, good manufacturing practices, proper sanitization measures, and new manufacturing guidelines. Although several Company customers have experienced business shutdowns during the last few weeks, this has dramatically impacted our online ordering and/or initiating new direct shipment orders. Additional COVID operating requirements to insure safety, handling requirements, sanitation requirements have placed a significant burden on order processing and fulfilment.
ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
Sales of unregistered securities during the six months ended June 30, 2022 are as follows:
From January 1, 2022 through June 30, 2022 the Company issued an aggregate of 51,282 shares of Common Stock under its Reg A-1 registration currently in effect and an additional 312,008 shares of common stock to various consultants for services.
From January 1, 2022 through June 30, 2022 the Company issued an aggregate of 190,505 and 13,704 shares of Common Stock under various asset acquisition agreements and acquisition of property and equipment, respectively.
From January 1, 2022 through June 30, 2022 the Company issued an aggregate of 10,150 shares of Common Stock under various interest conversion agreements.
From January 1, 2022 through June 30, 2022 the Company converted 15 shares of Series A Preferred Stock to 33,345 shares of Common Stock.
With respect to the transactions noted above, each of the recipients of securities of the Company was an accredited investor, or is considered by the Company to be a “sophisticated person”, inasmuch as each of them has such knowledge and experience in financial and business matters that they are capable of evaluating the merits and risks of receiving securities of the Company. No solicitation was made and no underwriting discounts were given or paid in connection with these transactions. The Company believes that the issuance of its securities as described above was exempt from registration with the Securities and Exchange Commission pursuant to Section 4(a)(2) and/or Regulation D of the Securities Act of 1933.
C:
| 20 |
ITEM 3. DEFAULTS UPON SENIOR SECURITIES
None.
ITEM 4. MINE SAFETY DISCLOSURES
Not applicable.
None.
The following exhibits are filed with this offering circular:
C:
| 21 |
| (1) | Filed with the Annual Report on Form 10-K filed with the SEC on April 2, 2020 and incorporated herein by reference. |
| (2) | Filed with the Form S-1 Registration Statement filed with the SEC on December 2, 2015 and incorporated herein by reference. |
| (3) | Filed with the Current Report on Form 8-K filed with the SEC on January 30, 2019 and incorporated herein by reference. |
| (4) | Filed with the Current Report on Form 8-K filed with the SEC on December 6, 2019 and incorporated herein by reference. |
| (5) | Filed with the Current Report on Form 8-K filed with the SEC on February 18, 2020 and incorporated herein by reference. |
| (6) | Filed with the Current Report on Form 8-K filed with the SEC on January 15, 2019 and incorporated herein by reference. |
| (7) | Filed with the Form 1-A/A, Part II, filed with the SEC on July 17, 2020 and incorporated herein by reference. |
| (8) | Filed with the Form 1-A POS, Part II, filed with the SEC on September 11, 2020 and incorporated herein by reference. |
| (9) | Filed with the Current Report on Form 8-K filed with the SEC on November 23, 2020 and incorporated herein by reference. |
| (10) | Filed with the Annual Report on Form 10-K filed with the SEC on April 15, 2022 and incorporated herein by reference. |
| (11) | Filed with the Quarterly Report on Form 10-Q filed with the SEC on May 21, 2021 and incorporated herein by reference. |
| (12) | Filed with the Current Report on Form 8-K filed with the SEC on August 17, 2021 and incorporated herein by reference. |
| (13) | Filed with the Current Report on Form 8-K filed with the SEC on September 1, 2021 and incorporated herein by reference. |
| (14) | Filed with the Current Report on Form 8-K filed with the SEC on March 31, 2022 and incorporated herein by reference. |
| (15) | Filed with the Form 10-K filed with the SEC on April 15, 2022 and incorporated herein by reference. |
| (16) | Filed with the Current Report on Form 8-K filed with the SEC on April 29, 2022 and incorporated herein by reference. |
C:
| 22 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| Can B Corp. | ||
| Date: August 22, 2022 | By: | /s/ Marco Alfonsi |
| Marco Alfonsi, | ||
| Chief Executive Officer | ||
| Date: August 22, 2022 | By: | /s/ Stanley L. Teeple |
| Stanley L. Teeple, | ||
| Chief Financial Officer | ||
C:
| 23 |
| This ‘10-Q’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| 6/6/23 | ||||
| 4/22/23 | ||||
| 3/22/23 | ||||
| 12/31/22 | ||||
| 12/7/22 | ||||
| Filed on: | 8/22/22 | |||
| 8/21/22 | ||||
| 8/12/22 | ||||
| 8/5/22 | ||||
| 7/25/22 | 8-K | |||
| 7/18/22 | 8-K | |||
| For Period end: | 6/30/22 | NT 10-Q, S-1/A | ||
| 5/31/22 | ||||
| 5/25/22 | S-1/A | |||
| 4/30/22 | ||||
| 4/29/22 | 8-K | |||
| 4/15/22 | 10-K | |||
| 4/14/22 | ||||
| 4/1/22 | NT 10-K | |||
| 3/31/22 | 10-Q, 8-K, NT 10-Q | |||
| 3/3/22 | ||||
| 2/11/22 | S-1/A | |||
| 2/2/22 | ||||
| 1/31/22 | ||||
| 1/1/22 | ||||
| 12/31/21 | 10-K, NT 10-K | |||
| 11/24/21 | ||||
| 11/18/21 | ||||
| 11/7/21 | ||||
| 10/7/21 | ||||
| 9/1/21 | 253G2, 8-K | |||
| 8/17/21 | 8-K | |||
| 8/13/21 | ||||
| 8/12/21 | 8-K | |||
| 6/30/21 | 10-Q, S-1 | |||
| 5/21/21 | 10-Q | |||
| 4/28/21 | ||||
| 4/1/21 | ||||
| 3/27/21 | ||||
| 3/17/21 | ||||
| 3/16/21 | ||||
| 3/11/21 | 8-K | |||
| 3/10/21 | ||||
| 2/22/21 | ||||
| 2/8/21 | ||||
| 1/1/21 | ||||
| 11/23/20 | 8-K | |||
| 9/11/20 | 1-A POS | |||
| 7/17/20 | 1-A/A, CORRESP | |||
| 4/2/20 | 10-K | |||
| 3/11/20 | ||||
| 2/18/20 | 8-K | |||
| 1/16/20 | 8-K, PRE 14C | |||
| 12/6/19 | 8-K | |||
| 5/29/19 | 8-K | |||
| 2/1/19 | ||||
| 1/30/19 | 8-K | |||
| 1/15/19 | 8-K | |||
| 12/28/18 | 8-K, D | |||
| 11/29/18 | ||||
| 5/15/17 | NT 10-Q | |||
| 12/2/15 | S-1 | |||
| 10/11/05 | ||||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 4/29/22 Can B Corp. 8-K:1,2,3,9 4/13/22 15:859K M2 Compliance LLC/FA 4/15/22 Can B Corp. 10-K 12/31/21 66:5.8M M2 Compliance LLC/FA 3/31/22 Can B Corp. 8-K:1,2,3,9 3/23/22 18:48M M2 Compliance LLC/FA 9/01/21 Can B Corp. 8-K:1,9 6/14/21 13:10M M2 Compliance LLC/FA 8/17/21 Can B Corp. 8-K:1,2,3,8 8/12/21 14:1.7M M2 Compliance LLC/FA 5/21/21 Can B Corp. 10-Q 3/31/21 69:3.9M M2 Compliance LLC/FA 4/14/21 Can B Corp. 10-K 12/31/20 102:84M M2 Compliance LLC/FA 11/23/20 Can B Corp. 8-K:5,9 11/17/20 2:4.6M M2 Compliance LLC/FA 9/11/20 Can B Corp. 1-A POS 5:1.8M M2 Compliance LLC/FA 7/17/20 Can B Corp. 1-A/A 7:5.1M M2 Compliance LLC/FA 4/02/20 Can B Corp. 10-K 12/31/19 83:40M M2 Compliance LLC/FA 1/30/19 Can B Corp. 8-K:5,9 1/14/19 3:367K Printing & Proxy, LLC/FA 12/02/15 Can B Corp. S-1 15:64M Printing & Proxy, LLC/FA |